Top

Published in:

01-08-2017 | REVIEW

Lung cancer and β-glucans: review of potential therapeutic applications

Authors: Raheleh Roudi, Shahla Roudbar Mohammadi, Maryam Roudbary, Monireh Mohsenzadegan

Published in: Investigational New Drugs | Issue 4/2017

Summary

The potential of natural substances with immunotherapeutic properties has long been studied. β-glucans, a cell wall component of certain bacteria and fungi, potentiate the immune system against microbes and toxic substances. Moreover, β-glucans are known to exhibit direct anticancer effects and can suppress cancer proliferation through immunomodulatory pathways. Mortality of lung cancer has been alarmingly increasingly worldwide; therefore, treatment of lung cancer is an urgent necessity. Numerous researchers are now dedicated to using β-glucans as a therapy for lung cancer. In the present attempt, we have reviewed the studies addressing therapeutic effects of β-glucans in primary and metastatic lung cancer published in the time period of 1991–2016.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. doi:10.3322/caac.21332 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262 CrossRefPubMed

Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380. doi:10.1056/NEJMra0802714 CrossRefPubMed

Youlden DR, Cramb SM, Baade PD (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 3:819–831. doi:10.1097/JTO.0b013e31818020eb CrossRefPubMed

Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K (2007) Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:234s–42s. doi: 10.1378/chest.07-1378

Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW (2007) Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. Chest 132:243S–265S. doi:10.1378/chest.07-1379 CrossRefPubMed

Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris H-B (2005) Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg 80:268–275. doi:10.1016/j.athoracsur.2005.02.005 CrossRefPubMed

Reck M, Heigener DF, Mok T, Soria J-C, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719. doi:10.1016/S0140-6736(13)61502-0 CrossRefPubMed

Afanasjeva J, Hui RL, Spence MM, Chang J, Schottinger JE, Millares M, Rashid N (2016) Identifying subsequent therapies in patients with advanced non–small cell lung cancer and factors associated with overall survival. Pharmacotherapy 36:1065–1074. doi:10.1002/phar.1826 CrossRefPubMed

10.

Nassar D, Blanpain C (2016) Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol 11:47–76. doi:10.1146/annurev-pathol-012615-044438 CrossRefPubMed

11.

Soltanian S, Matin MM (2011) Cancer stem cells and cancer therapy. Tumour Biol 32:425–440. doi:10.1007/s13277-011-0155-8 CrossRefPubMed

12.

Roudi R, Madjd Z, Ebrahimi M, Najafi A, Korourian A, Shariftabrizi A, Samadikuchaksaraei A (2016) Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumour Biol 37:11843–11859. doi:10.1007/s13277-016-5041-y CrossRefPubMed

13.

Roudi R, Korourian A, Shariftabrizi A, Madjd Z (2015) Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Investig 33:294–302. doi:10.3109/07357907.2015.1034869 CrossRef

14.

Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, Shariftabrizi A (2014a) Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark 14:457–467. doi:10.3233/CBM-140424 CrossRefPubMed

15.

Roudi R, Madjd Z, Ebrahimi M, Samani FS, Samadikuchaksaraei A (2014b) CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol Biol Lett 19:23–36. doi:10.2478/s11658-013-0112-1 CrossRefPubMed

16.

O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. doi:10.1038/nature05372 CrossRefPubMed

17.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. doi:10.1158/0008-5472.CAN-05-2018 CrossRefPubMed

18.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988. doi:10.1073/pnas.0530291100 CrossRefPubMedPubMedCentral

19.

Li F, Zhou K, Gao L, Zhang B, Li W, Yan W (2016) Radiation induces the generation of cancer stem cells: a novel mechanism for cancer radioresistance. Oncol Lett 12:3059–3065. doi:10.3892/ol.2016.5124 PubMedPubMedCentral

20.

Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G (2013) Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27:13–24. doi:10.1096/fj.12-218222 CrossRefPubMed

21.

Luo J, Shen L, Zheng D (2014) Association between vitamin C intake and lung cancer: a dose-response meta-analysis. Sci Rep 4:6161. doi:10.1038/srep06161 CrossRefPubMedPubMedCentral

22.

Zhang L, Wang S, Che X, Li X (2015) Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem 36:299–305. doi:10.1159/000374072 CrossRefPubMed

23.

Aleem E (2013) β-glucans andtheir applications in cancer therapy: focus on human studies. Anti Cancer Agents Med Chem 13:709–719

24.

Tokunaka K, Ohno N, Adachi Y, Miura NN, Yadomae T (2002) Application of Candida solubilized cell wall β-glucan in antitumor immunotherapy against P815 mastocytoma in mice. Int Immunopharmacol 2:59–67CrossRefPubMed

25.

Tokunaka K, Ohno N, Adachi Y, Tanaka S, Tamura H, Yadomae T (2000) Immunopharmacological and immunotoxicological activities of a water-soluble (1→ 3)-β-d-glucan, CSBG from Candida spp. Int J Immunopharmacol 22:383–394CrossRefPubMed

26.

Baur S, Geisler G (1996) Variability of the beta-glucan content in oat caryopsis of 132 cultivated-oat genotypes and 39 wild-oat genotypes. J Agron Crop Sci 176:151–157

27.

Borchers AT, Keen CL, Gershwin ME (2004) Mushrooms, tumors, and immunity: an update. Exp Biol Med (Maywood) 229:393–406

28.

Wasser S (2002) Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60:258–274. doi:10.1007/s00253-002-1076-7 CrossRefPubMed

29.

Chan WK, Lam DTW, Law HKW, Wong WT, Leung Koo MW, Lau ASY, Chan GC (2005) Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med 11:1047–1057. doi:10.1089/acm.2005.11.1047 CrossRefPubMed

30.

Vetvicka V, Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin JC (2007) Orally administered marine (1→ 3)-β-D-glucan Phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol 40:291–298CrossRefPubMed

31.

Driscoll M, Hansen R, Ding C, Cramer DE, Yan J (2009) Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther 8:218–225CrossRefPubMed

32.

Brown GD, Gordon S (2003) Fungal β-glucans and mammalian immunity. Immunity 19:311–315CrossRefPubMed

33.

Ishibashi K-I, Miura NN, Adachi Y, Ohno N, Yadomae T (2001) Relationship between solubility of grifolan, a fungal 1, 3-β-D-glucan, and production of tumor necrosis factor by macrophages in vitro. Biosci Biotechnol Biochem 65:1993–2000CrossRefPubMed

34.

Lee D-Y, Ji I-H, Chang H-I, C-W KIM (2002) High-level TNF-α secretion and macrophage activity with soluble β-glucans from Saccharomyces cerevisiae. Biosci Biotechnol Biochem 66:233–238. doi:10.1271/bbb.66.233 CrossRefPubMed

35.

Ahmad A, Munir B, Abrar M, Bashir S, Adnan M, Tabassum T (2012) Perspective of β-glucan as functional ingredient for food industry. J Nutr Food Sci 2:2CrossRef

36.

Gulcelik MA, Dincer H, Sahin D, Faruk DO, Yenidogan E, Alagol H (2010) Glucan improves impaired wound healing in diabetic rats. Wounds 22:12–16PubMed

37.

Kim J-Y, Jun J-H, Kim S-J, Hwang K-M, Choi SR, Han SD, Son MW, Park ES (2015) Wound healing efficacy of a chitosan-based film-forming gel containing tyrothricin in various rat wound models. Arch Pharm Res 38:229–238. doi:10.1007/s12272-014-0368-7 CrossRefPubMed

38.

Delatte SJ, Evans J, Hebra A, Adamson W, Othersen HB, Tagge EP (2001) Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr Surg 36:113–118. doi:10.1053/jpsu.2001.20024 CrossRefPubMed

39.

Cheung N-KV, Modak S, Vickers A, Knuckles B (2002) Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51:557–564. doi:10.1007/s00262-002-0321-3 PubMed

40.

Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM (2013) Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol 20(10):1585–1591. doi:10.1128/CVI.00463-13 CrossRefPubMedPubMedCentral

41.

Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW, Williams DL (2002) Human monocyte scavenger receptors are pattern recognition receptors for (1→ 3)-β-D-glucans. J Leukoc Biol 72(1):140–146PubMed

42.

Herre J, Gordon S, Brown GD (2004)Dectin-1 and its role in the recognition of β-glucans by macrophages. Mol Immunol 40:869–876CrossRefPubMed

43.

Schorey J, Lawrence C (2008) Thepattern recognition receptor Dectin-1: from fungi to mycobacteria. Curr Drug Targets 9:123–129

44.

Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT, DeMong DE (1998) A novel carbohydrate-glycosphingolipid interaction between a β-(1–3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem 273:22014–22020CrossRefPubMed

45.

Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, Wong SY (2002) The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol 169:3876–3882CrossRefPubMed

46.

Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003) Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2. J Exp Med 197:1107–1117CrossRefPubMedPubMedCentral

47.

Yadav M, Schorey JS (2006) The β-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 108:3168–3175. doi:10.1182/blood-2006-05-024406 CrossRefPubMedPubMedCentral

48.

Rubin-Bejerano I, Abeijon C, Magnelli P, Grisafi P, Fink GR (2007) Phagocytosis by humanneutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe 2:55–67. doi:10.1016/j.chom.2007.06.002

49.

Goodridge HS, Simmons RM, Underhill DM (2007) Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol 178:3107–3115CrossRefPubMed

50.

Gross O, Gewies A, Finger K, Schäfer M, Sparwasser T, Peschel C, Förster I, Ruland J (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442:651–656. doi:10.1038/nature04926 CrossRefPubMed

51.

Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, Reisesousa C (2005) Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22:507–517. doi:10.1016/j.immuni.2005.03.004 CrossRefPubMed

52.

Roudbary M, Daneshmandi S, Hajimoradi M, Roudbarmohammadi S, Hassan ZM (2015) Immunomodulatory effect of β-glucan on peritoneal macrophages of Bab1/c mice. Pol J Microbiol 64:175–179PubMed

53.

Kournikakis B, Mandeville R, Brousseau P, Ostroff G (2003) Anthrax-protective effects of yeast beta 1, 3 glucans. MedGenMed 5:1PubMed

54.

Medeiros SD, Cordeiro SL, Cavalcanti JE, Melchuna KM, Lima AM, Filho IA, Medeiros AC, Rocha KB, Oliveira EM, Faria ED, Sassaki GL, Rocha HA, Sales VS (2012) Effects of purified Saccharomyces cerevisiae (1→ 3)-β-glucan on venous ulcer healing. Int J Mol Sci 13:8142–8158. doi:10.3390/ijms13078142

55.

McIntosh M, Stone B, Stanisich V (2005) Curdlan and other bacterial (1→ 3)-β-D-glucans. Appl Microbiol Biotechnol 68:163–173. doi:10.1007/s00253-005-1959-5 CrossRefPubMed

56.

Kidd PM (2000) The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5:4–27PubMed

57.

Han S-SR, Cho C-K, Lee Y-W, Yoo H-S (2009) Antimetastatic and immunomodulating effect of water extracts from various mushrooms. J Acupunct Meridian Stud 2:218–227. doi:10.1016/S2005-2901(09)60058-3 CrossRefPubMed

58.

Kulicke W-M, Lettau AI, Thielking H (1997) Correlation between immunological activity, molar mass, and molecular structure of different (1→ 3)-β-D-glucans. Carbohydr Res 297:135–143CrossRefPubMed

59.

Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, Nakazawa S, Oka M (2009) Efficacy of orally administered superfine dispersed lentinan (β-1, 3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 29:2611–2617PubMed

60.

Demir G, Klein H, Mandel-Molinas N, Tuzuner N (2007) Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7:113–116. doi:10.1016/j.intimp.2006.08.011 CrossRefPubMed

61.

Nasrollahi Z, Mohammadi SR, Mollarazi E, Yadegari MH, Hassan ZM, Talaei F, Dinarvand R, Akbari H, Atyabi F (2015) Functionalized nanoscale β-1, 3-glucan to improve Her2+ breast cancer therapy: in vitro and in vivo study. J Control Release 202:49–56. doi:10.1016/j.jconrel.2015.01.014 CrossRefPubMed

62.

Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, Morrot A, Zavala F, Steinman RM, Nussenzweig RS, Nussenzweig MC (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203:599–606. doi:10.1084/jem.20051639 CrossRefPubMedPubMedCentral

63.

Suzuki I, Sakurai T, Hashimoto K, Oikawa S, Masuda A, Ohsawa M, Yadomae T (1991) Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered beta-glucan in mice. Chem Pharm Bull (Tokyo) 39:1606–1608CrossRef

64.

Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH (2008) Anti-tumor metastatic activity of β-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol 8:36–42. doi:10.1016/j.intimp.2007.10.005 CrossRefPubMed

65.

Lin H, Cheung SW, Nesin M, Cassileth BR, Cunningham-Rundles S (2007) Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production. Clin Vaccine Immunol 14:21–27. doi:10.1128/CVI.00284-06 CrossRefPubMed

66.

Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, Inagaki K, Kondo T, Kurita N, Suzuki M, Kanayama N, Terao T (2005) Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol 131:527–538. doi:10.1007/s00432-005-0672-1 CrossRefPubMed

67.

Yamamoto K, Kimura T, Sugitachi A, Matsuura N (2009) Anti-angiogenic and anti-metastatic effects of β-1, 3-D-glucan purified from Hanabiratake, Sparassis crispa. Biol Pharm Bull 32:259–263CrossRefPubMed

68.

Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J (2010) Orally administered particulate β-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res 16:5153–5164. doi:10.1158/1078-0432.CCR-10-0820 CrossRefPubMedPubMedCentral

69.

Queiroz EA, Fortes ZB, da Cunha MA, Barbosa AM, Khaper N, Dekker RF (2015) Antiproliferative and pro-apoptotic effects of three fungal exocellular β-glucans in MCF-7 breast cancer cells is mediated by oxidative stress, AMP-activated protein kinase (AMPK) and the Forkhead transcription factor, FOXO3a. Int J Biochem Cell Biol 67:14–24. doi:10.1016/j.biocel.2015.08.003 CrossRefPubMed

70.

Kogan G, Šandula J, Korolenko TA, Falameeva OV, Poteryaeva ON, Zhanaeva SY, Levina OA, Filatova TG, Kaledin VI (2002) Increased efficiency of Lewis lung carcinoma chemotherapy with a macrophage stimulator—yeast carboxymethyl glucan. Int Immunopharmacol 2:775–781CrossRefPubMed

71.

Vetvicka V, Vetvickova J (2012) Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potential. Anticancer Res 32:81–87PubMed

72.

Friedenreich CM, Orenstein MR (2002) Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132:3456S–3464SPubMed

73.

Greenwald P, Clifford C, Milner J (2001) Diet and cancer prevention. Eur J Cancer 37:948–965CrossRefPubMed

74.

Murphy E, Davis J, Brown AS, Carmichael MD, Mayer EP, Ghaffar A (2004) Effects of moderate exercise and oat β-glucan on lung tumor metastases and macrophage antitumor cytotoxicity. J Appl Physiol 97:955–959. doi:10.1152/japplphysiol.00252.2004

75.

Vrouenraets MB, Visser G, Snow G, Van Dongen G (2003) Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 23:505–522PubMed

76.

Akramiene D, Aleksandraviciene C, Grazeliene G, Zalinkevicius R, Suziedelis K, Didziapetriene J, Simonsen U, Stankevicius E, Kevelaitis E (2010) Potentiating effect of β-glucans on photodynamic therapy of implanted cancer cells in mice. Tohoku J Exp Med 220:299–306CrossRefPubMed

77.

Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD (2004) Mechanism by which orally administered β-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173:797–806CrossRefPubMed

78.

Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan J (2007) Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 67:7421–7430. doi:10.1158/0008-5472.CAN-07-1465 CrossRefPubMedPubMedCentral

79.

Zhong W, Hansen R, Li B, Cai Y, Salvador C, Moore GD, Yan J (2009) Effect of yeast-derived β-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. J Immunother 32:703–712. doi:10.1097/CJI.0b013e3181ad3fcf CrossRefPubMed

80.

Vetvicka V, Vetvickova J (2015) Glucan supplementation has strong anti-melanoma effects: role of NK cells. Anticancer Res 35:5287–5292PubMed

81.

Lo TC-T, Hsu F-M, Chang CA, Cheng JC-H (2011) Branched α-(1, 4) glucans from Lentinula edodes (L10) in combination with radiation enhance cytotoxic effect on human lung adenocarcinoma through the toll-like receptor 4 mediated induction of THP-1 differentiation/activation. J Agric Food Chem 59:11997–12005CrossRefPubMed

82.

Byun EB, Park SH, Jang BS, Sung NY, Byun EH (2016) Gamma-irradiated β-glucan induces immunomodulation and anticancer activity through MAPK and NF-κB pathways. J Sci Food Agric 96:695–702. doi:10.1002/jsfa.7215 CrossRefPubMed

83.

Albeituni SH, Ding C, Liu M, Hu X, Luo F, Kloecker G, Bousamra M 2nd, Zhang HG, Yan J (2016) Yeast-derived particulate β-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to apc in cancer. J Immunol 196:2167–2180. doi:10.4049/jimmunol.1600346 CrossRefPubMedPubMedCentral

84.

Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology 13:591–599. doi:10.1093/neuonc/nor042 CrossRefPubMedPubMedCentral

85.

Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, Lang S (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311–317. doi:10.1189/jlb.0310162 CrossRefPubMed

86.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. doi:10.1007/s00262-008-0523-4 CrossRefPubMed

87.

Iclozan C, Antonia S, Chiappori A, Chen D-T, Gabrilovich D (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62:909–918. doi:10.1007/s00262-013-1396-8 CrossRefPubMedPubMedCentral

88.

Kodama N, Komuta K, Nanba H (2002) Can maitake MD-fraction aid cancer patients? Altern Med Rev 7:236–239PubMed

89.

Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, Chan E, Koh HL, Li X, Zhou S (2005) Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 8:159–168CrossRefPubMed

90.

Weitberg AB (2008) A phase I/II trial of beta-(1, 3)/(1, 6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J Exp Clin Cancer Res 27:40. doi:10.1186/1756-9966-27-40 CrossRefPubMedPubMedCentral

Title: Lung cancer and β-glucans: review of potential therapeutic applications
Authors: Raheleh Roudi
Shahla Roudbar Mohammadi
Maryam Roudbary
Monireh Mohsenzadegan
Publication date: 01-08-2017
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0449-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer